eISSN: 2449-8238
ISSN: 2392-1099
Clinical and Experimental Hepatology
Current issue Archive Manuscripts accepted About the journal Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
2/2017
vol. 3
 
Share:
Share:
more
 
 
abstract:
Review paper

Recommendations for the treatment of hepatitis C in 2017

Waldemar Halota, Robert Flisiak, Jacek Juszczyk, Piotr Małkowski, Małgorzata Pawłowska, Krzysztof Simon, Krzysztof Tomasiewicz

Clin Exp HEPATOL 2017; 3, 2: 47–55
Online publish date: 2017/05/18
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
The goals of treatment is to eliminate HCV infection, stop or reverse histological changes, reduce the risk of hepatocellular carcinoma development and transmission of the infection to other individuals. According to the recommendation of the Polish Group of Experts for HCV in 2017 all patients with chronic HCV infection should receive treatment, but it is not recommended in patients at high risk of short overall survival. If access to therapy is restricted, priority should be given to patients whose HCV infection can lead to an unfavourable outcome of the disease within a short time frame, particular to individuals with liver cirrhosis, rapidly progressing liver fibrosis, extrahepatic manifestations of HCV infection, chronic kidney diseases, patients before and after organ transplantation. Current recommendations of Polish Group of Experts for HCV provide guidelines to select optimal medication, assessment of liver fibrosis, treatment efficacy, dealing with resistance to direct acting antivirals, monitoring for hepatocellular carcinoma, management of HBV/HCV coinfection and drug interactions. It constains also advice on treatment of special patients populations such as renal failure, liver transplant and hepatic decompensation, as well as retreatment of patients which failed interferon free therapy. Moreover specific recommendations of management patients infected with different genotypes with currently reimbursed regimens or those expected to become available shortly in Poland are also included.
references:
Wedemeyer H, Dore GJ, Ward JW. Estimates on HCV disease burden worldwide – filling the gaps. J Viral Hepatitis 2015; 22 (Suppl 1): 1-5.
Flisiak R, Halota W, Horban A, et al. Analysis of risk factors related to HCV infection in Poland. Eur J Gastroenterol Hepatol 2011; 23: 1213-1217.
Flisiak R, Halota W, Tomasiewicz K, et al. Forecasting the disease burden of chronic hepatitis C virus in Poland. Eur J Gastroenterol Hepatol 2015; 27: 70-76.
Flisiak R, Pogorzelska J, Berak H, et al. Prevalence of HCV genotypes in Poland – the EpiTer study. Clin Exp Hepatol 2016; 2: 144-148.
Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol 2014; 61: S58-68.
Halota W, Flisiak R, Boroń-Kaczmarska A, et al.; Polish Group of HCV Experts. Recommendations for the treatment of hepatitis C issued by the Polish Group of HCV Experts – 2016. Clin Exp Hepatol 2016; 2: 27-33.
EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatology 2017; 66: 153-194.
Basu P, Niraj JS, Nimy J, et al. Sofosbuvir and Ledipasvir versus Sofosbuvir and Simeprevir combination therapy in the management of acute hepatitis C: A randomized open label prospective clinical pilot study. SLAM C study. Interim data. AASLD 2015; 110318, ID: 1074.
Jaroszewicz J, Flisiak-Jackiewicz M, Lebensztejn D, et al. Current drugs in early development for treating hepatitis C virus- related hepatic fibrosis. Expert Opin Investig Drugs 2015; 24: 1229-1239.
www.hepatitisc.uw.edu/page/clinical-calculators/apri.
Kobayashi M, Suzuki F, Fujiyama S, et al. Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection. J Med Virol 2017; 89: 476-483.
ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CirVir and CO23 CUPILT cohorts). Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts. J Hepatol 2016; 65: 734-740.
Nault JC, m Colombo: Hepatocellular carcinoma and direct acting antiviral treatments: Controversy after revolution. J Hepatol 2016; 65: 741-747.
Calvaruso V et al. Early occurence of hepatocellular carcinoma (HCC) in patients with HCV cirrhosis treated with direct-acting antivirals (DAAs). EASL HCC Summit, Geneva, 2-5 February 2017. COO3.
Cavaletto L et al. Comparison between de-novo occurence and recurrence of hepatocellular carcinoma (HCC) after direct-acting antivirals (DAAs) in cirrhotic patients with hepatitis C: A real-life cohort study. EASL HCC Summit, Geneva, 2-5 February 2017. PIO.05.
Kolly P et al. Hepatocellular carcinoma after direct antiviral agent treatment: A European Multicenter study. EASL HCC Summit, Geneva, 2-5 February 2017. PII.09-YI.
Gheorghe L et al. Alpha fetoprotein – a useful for follow-up of interferon-free treated cirrhotic patients with de novo hepatocellular carcinoma after SVR. EASL HCC Summit, Geneva, 2-5 February 2017. PI2.09.
Castano A et al. Alpha fetoprotein (AFP) levels before and after sustained virological response with direct-acting antivirals (DAAs) in patients with liver cirrhosis due to hepatitis C virus (HCV). EASL HCC Summit, Geneva, 2-5 February 2017. PI3.04-YI.
Conti F, Buonfiglioli F, Scuteri A, et al. Early occurence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated direct-acting antivirals. J Hepatol 2016; 65: 727-733.
Reig M, Mariño Z, Perelló C, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol 2016; 65: 719-726.
Wasiak D, Małkowski P. Wytyczne leczenia raka wątrobowokomórkowego (HCC). Med Sci Mon Rev Hepatology 2013; 13: 112-115.
Bersoff-Matcha SJ, Cao K, Jason M, et al. Hepatitis B Reactivation in Patients Receiving Interferon-Free Direct Acting Antiviral Agents for Chronic Hepatitis C Virus Infection. AASLD 2016 Nov 11-15 Boston.
AASLD/IDSA Recomendations for Testing, Managing, and Treating Hepatitis C updated, Sep 2016.
Ende AR, Kim NH, Yeh MM, et al. Fulminant hepatitis B reactivation leading to liver transplantation in a patient with chronic hepatitis C treated with simeprevir and sofosbuvir: a case report. J Med Case Rep 2015; 9: 164.
Badri P, Dutta S, Coakley E. Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir. Am J Transplant 2015; 15: 1313-1322.
www.hep-druginteractions.org.
Flisiak R, Janczewska E, Wawrzynowicz-Syczewska M, et al. Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin in hepatitis C: AMBER study. Aliment Pharmacol Ther 2016; 44: 946-956.
Juszczyk J. Hepatitis C, patogeneza i terapia. Termedia, Poznań 2016.
Calleja JL, Crespo J, Rincón D, et al. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: results from a Spanish real world cohort. J Hepatol 2017; doi: 10.1016/j.jhep.2017.01.028. [Epub ahead of print].
Viekirax, Charakterystyka Produktu Leczniczego.
Exviera, Charakterystyka Produktu Leczniczego.
Harvoni, Charakterystyka Produktu Leczniczego.
Flisiak R, Pogorzelska J, Berak H, et al. Efficacy of HCV treatment in Poland at the turn of the interferon era – the EpiTer study. Clin Exp Hepatol 2016; 2: 138-143.
Flisiak R, Łucejko M, Mazur W, et al. Effectiveness and safety of ledipasvir/sofosbuvir ± ribavirin in the treatment of HCV infection: The real-world HARVEST study. Adv Med Sci 2017 [In press].
Daklinza, Charakterystyka Produktu Leczniczego.
Kumada H, Suzuki Y, Ikeda K i wsp. Daclatasvir plus Asunaprevir for chronic HCV genotype 1b infection. Hepatology 2014; 59: 2083-2091.
Manns M, Pol S, Jacobson IM, et al. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet 2014; 384: 1597-1605.
Zepatier, Charakterystyka Produktu Leczniczego.
Epclusa, Charakterystyka Produktu Leczniczego.
Pegasys, Charakterystyka Produktu Leczniczego.
Pegintron, Charakterystyka Produktu Leczniczego.
Sovaldi, Charakterystyka Produktu Leczniczego.
Cornberg M, Petersen J, Schober A, et al. Real-world use, effectiveness and safety of anti-viral treatment in chronic hepatitis C genotype 3 infection. Aliment Pharmacol Ther 2017; 45: 688-700.
FEATURED PRODUCTS
Quick links
© 2018 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe